患者服用抗发药物的事先授权,数量限制和步骤治疗
Kaitlyn Vu1, Arjun Gupta2, Fumiko Chino3
1Harvard College, Cambridge, Massachusetts.
JAMA network open
|October 6, 2025
概括
对抗嘔吐药物的利用管理政策在"可负担医疗法案" (ACA) 市场和医疗补助计划之间有很大差异,影响着仿制药和品牌药物. 这些政策的标准化可以减少患者的行政负担.
科学领域:
- 在瘤学瘤学.
- 卫生政策 卫生政策
- 药物经济学 药物经济学
背景情况:
- 抗药对癌症患者的生活质量和治疗坚持至关重要,得到1级证据的支持.
- 使用管理 (UM) 策略,如事先授权,步骤治疗和数量限制,被保险公司用于控制成本和优化药物使用.
研究的目的:
- 分析和描述患者保护和可负担医疗法案 (ACA) 市场和医疗补助保险计划中的反药的UM政策.
- 为了识别UM在不同计划类型,药物配方和地理区域的变化.
主要方法:
- 一项横截面研究分析了2024年医疗补助和ACA药物配方的全国样本.
- 数据与FDA国家药物规范联系在一起,以确定13种常见的自给药抗药的配方.
- 评估了UM政策 (事先授权,数量限制,步骤治疗) 对这些抗药的应用.
主要成果:
- 在ACA计划中,UM影响了39.7%的抗药,在医疗补助计划中影响了43.4%.
- ACA计划限制了通用 (40.5%) 与品牌 (17.4%) 抗药的比例较高.
- 医疗补助计划限制了更高比例的品牌 (82.5%) 和通用 (42.2%) 抗emetics.
- 量限制是最常见的UM工具,适用于两种计划类型中超过三分之一的抗药.
- 在各州和计划之间观察到UM政策的显著差异.
结论:
- 在各类保险 (ACA,Medicaid),各州和药物特征中,UM对抗药物的要求存在实质性的变化.
- 这些变化可能会给治疗癌症的患者带来行政负担.
- 标准化UM政策可能会改善患者的接入,并减少行政障碍.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
780
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
780
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
562
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
562
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
511
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
511
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
646
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
646
Dosage Regimen: Individualization
146
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
146
Drug Therapy
226
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
226


